Delivery Order 36F79721D0166-36C24926F0152

<p>Veterans Integrated Service Network 20 issued a $151,464.65 delivery order to Biocryst Pharmaceuticals Inc. on May 19, 2026, for ORLADEYO 150mg capsules under the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB).</p> <p>Place of performance is Earth City, Missouri. The order is firm fixed price with an ultimate completion date of September 30, 2026. No set-aside was used.</p>

This federal contract award was made by the Veterans Integrated Service Network 20 (VISN 20), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in rare disease pharmaceuticals. The $379,939.32 firm fixed-price delivery order contract is for the supply of BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO), a medication used to treat hereditary angioedema. The contract has an ultimate completion date of September 30, 2025 and was awarded on October 1, 2024. The...

This is a $382,300.88 firm fixed-price delivery order contract awarded by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing drugs for rare diseases. The contract is for the bulk order of ORLADEYO, a drug used to treat hereditary angioedema, to support veteran healthcare. The contract is not set aside and is part of Biocryst's Federal Supply Schedule (FSS)...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $113,440.80 delivery order to Biocryst Pharmaceuticals, Inc. under the firm fixed price Pharmaceuticals and Drugs Federal Supply Schedule contract. This order is for the delivery of BEROTRALSTAT HCL 150MG CAP,ORAL BULK to the place of performance in Durham, North Carolina by May 31, 2023. The contract was awarded on June 1, 2022 and has no set-aside designation. Biocryst...

This is a delivery order contract awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is valued at $201,721.59 and has an ultimate completion date of October 4, 2024. The contract is for the delivery of ORLADEYO 150MG CAPS, a pharmaceutical product used to treat hereditary angioedema. The contract was awarded by the U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated...

Biocryst Pharmaceuticals, Inc. was awarded a $56,670.76 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The contract calls for the delivery of berotralstat to Roseburg, Oregon with a period of performance concluding on January 19, 2024. No set-aside designation was applied to this award issued against GSA Schedule 61-IB for pharmaceutical...

This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...

<p>This is a $85,080.60 firm fixed-price purchase order awarded by the Veterans Integrated Service Network 6 (VISN 6), a civilian agency, to Optime Care Inc. for the delivery of Orladeyo 150MG medication directly to patients. The award resulted from a pre-solicitation notice posted on October 18, 2022, with a due date of October 24, 2022. The contract has an ultimate completion date of January 23, 2023 and does not have a set-aside designation.</p>

The Department of Veterans Affairs, Veterans Integrated Service Network 9 (VISN 9), awarded a $364,139.25 firm fixed-price delivery order to Bristol-Myers Squibb Company for the supply of BREYANZI (lisocabtagene maraleucel), a chimeric antigen receptor T-cell therapy used to treat non-Hodgkin lymphoma. Awarded on May 29, 2026 with an ultimate completion date of August 31, 2026, this delivery order carries no set-aside designation and will be performed at Bristol-Myers Squibb's facility in...

This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to CSL Behring L.L.C., a global biotherapeutics company, for the provision of the emergency blood product Berinert. The contract has a ceiling value of $78,796.08 and is a firm fixed price delivery order issued under CSL Behring's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which has a total ceiling value of $201,482,280 and is valid through September 2026. The delivery...